Drug intelligence / Profile preview

AD-221

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-221 is an incrementally modified small molecule drug developed by Addpharma, a subsidiary of Yuhan, for the treatment of hyperlipidaemia and primary hypercholesterolemia. It has reached phase 3 clinical trials for these indications. The specific mechanism of action and molecular target have not been disclosed in public sources. The drug is administered orally and is being developed primarily in Korea.

Other names: incrementally modified drug

Beyond the preview

Go deeper on AD-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-221.

Explore the full profile